Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes.
This study investigates whether urinary levels of pentosidine, pyrraline and acrolein adduct are increased in type 2 diabetes (DM), and whether these levels are correlated with glycemic control and clinical traits. Urinary levels of pentosidine, pyrraline and acrolein adduct in DM patients (n = 100) recruited from the outpatient clinic of our university hospital were compared with those of age- and sex-matched non-diabetic subjects (n = 50). The correlation of these urinary levels with the glycemic control and the clinical traits were examined. Furthermore, the influence of smoking habit on the levels of acrolein adduct was examined. Urinary levels of pentosidine, pyrraline and acrolein adduct were all significantly (p<0.001) higher in the DM group than in the non-DM group (pentosidine (log(pmol/mgCr)), 1.579 +/- 0.147 vs 1.427 +/- 0.142; pyrraline (log(nmol/mgCr)), 0.888 +/- 0.402 vs 0.581 +/- 0.336; acrolein adduct (log(nmol/mgCr)), 2.316 +/- 0.221 vs 2.051 +/- 0.201). Glycemic control parameters, such as fasting plasma glucose (FPG) and HbA1c, were significantly correlated with these urinary levels. Age was correlated with the urinary levels of pentosidine but not with those of pyrraline and acrolein adduct. The urinary albumin excretion rate did not correlate with any of these urinary levels. The levels of acrolein adduct were higher in the subjects with smoking habit than in those without the habit in the DM group as well as in the non-DM group (DM, 2.391 +/- 0.230 and 2.212 +/- 0.190, p=0.0004; Non-DM, 2.120 +/- 0.171 and 1.993 +/- 0.206, p=0.0503). The urinary levels of pentosidine, pyrraline and acrolein adduct were increased in DM and were significantly correlated with glycemic control levels. In addition, smoking habit seems to increase the urinary levels of acrolein adduct.
Third Department of Internal Medicine, Yamagata University School of Medicine, Yamagata 990-9585, Japan.
Makoto
M
Daimon
Kazuhiko
K
Sugiyama
Wataru
W
Kameda
Tamotsu
T
Saitoh
Toshihide
T
Oizumi
Akihiko
A
Hirata
Hiroshi
H
Yamaguchi
Hiroshi
H
Ohnuma
Masahiko
M
Igarashi
Takeo
T
Kato
D000171:Acrolein / Q000652:urine*; D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000652:urine*; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000652:urine*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000652:urine; D008239:Lysine / Q000031:analogs & derivatives* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D009646:Norleucine / Q000031:analogs & derivatives* / Q000652:urine*; D011758:Pyrroles / Q000652:urine*; D012907:Smoking
D011758:Pyrroles; C059571:2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine; D000171:Acrolein; D009646:Norleucine; D001120:Arginine; C062187:pentosidine; D008239:Lysine